Recent News Releases

For investor-related news, see our ASX releases here.

Month Year

Feb 7, 2025

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

94 percent of patients eliminated factor IX prophylaxis and remained free of continuous prophylaxis through four years post-treatment Mean factor IX activity levels were sustained at near normal...
Jan 23, 2025

Australia’s Therapeutic Goods Administration (TGA) Approves Registration of CSL’s ANDEMBRY® (garadacimab) for the Prevention of Recurrent Hereditary Angioedema (HAE) Attacks

Discovered and developed in Australia by CSL scientists, ANDEMBRY is CSL’s first monoclonal antibody treatment; reinforces company’s commitment to providing a wide range of treatment...

Show per page

Filter by Company: